Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dimethyl fumarate (DMF) Clear all
Completed Phase 4 Interventional Results available

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

NCT01873417
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
BG00012 (DMF)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
37
States / cities
Cullman, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 21, 2026, 10:43 PM EDT
Terminated No phase listed Observational

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.

NCT01632449
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Test product, Reference product
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

NCT00273364
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 21, 2026, 10:43 PM EDT
Terminated No phase listed Observational

Tecfidera and MRI for Brain Energy in MS

NCT02644083
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Dimethyl fumarate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 21, 2026, 10:43 PM EDT
Recruiting No phase listed Observational

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

NCT05658497
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Aurora, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

NCT01281111
View directory record Official record
Conditions
Healthy
Interventions
Dimethyl Fumarate (BG00012), Aspirin, BG00012 matching placebo, ASA matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 21, 2026, 10:43 PM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 4 Interventional Results available

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

NCT02410278
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate, montelukast, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
50
States / cities
Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

NCT03093324
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
ALKS 8700, Dimethyl Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

NCT01420458
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Experimental
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Sep 21, 2026, 10:43 PM EDT
Completed No phase listed Observational

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

NCT02099370
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 21, 2026, 10:43 PM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

NCT02343159
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate, Medication Event Monitoring System (MEMS), Adherence counseling
Drug · Device · Behavioral
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Homewood, Alabama • Pheonix, Arizona • Carlsbad, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 21, 2026, 10:43 PM EDT
Completed No phase listed Observational

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

NCT04834401
View directory record Official record
Conditions
Multiple Sclerosis, Covid19
Interventions
Not listed
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 21, 2026, 10:43 PM EDT
Completed No phase listed Observational

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

NCT02823951
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Rebif, Tecfidera
Drug
Lead sponsor
IMS HEALTH GmbH & Co. OHG
Industry
Eligibility
18 Years to 55 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo, Glatiramer Acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 21, 2026, 10:43 PM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

NCT05767736
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
10,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 21, 2026, 10:43 PM EDT
Terminated Phase 3 Interventional Results available

Tecfidera Slow-Titration Study

NCT02428231
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02337426
View directory record Official record
Conditions
Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
Interventions
Dimethyl Fumarate, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 21, 2026, 10:43 PM EDT
Completed No phase listed Observational

Risk Perception in Multiple Sclerosis

NCT05528666
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
High Efficacy Therapy (HET), Non High Efficacy Therapy (Non-HET)
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
4,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Interferon β-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 21, 2026, 10:43 PM EDT
Completed No phase listed Observational

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

NCT01903291
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 21, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

NCT01156311
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 21, 2026, 10:43 PM EDT